References in periodicals archive ?
There is a need for a device such as the Novacor LVAS, with a track record of reliability and durability", commented Professor Peter Alivizatos, director of the Heart Transplant department.
The Novacor LVAS has been marketed in Europe since 1994 as both a bridge to transplant and a long-term alternative to other medical therapies, such as chronic drug treatment and transplantation.
Following upon the INTrEPID feasibility study, WorldHeart is currently conducting a pivotal randomized study comparing the Novacor LVAS to an approved Destination Therapy device.
The Novacor LVAS is now available to hospitals in Canada for use on suitable patients as a bridge to heart transplantation.
Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation, risks in product development and market acceptance of and demand for the Company's products, risks associated with costs and delays posed by government regulation, limitations on third-party reimbursement, inability to protect any of its proprietary technology, including the patents discussed above, potential product liability, slower destination therapy adoption rate for VADs including our Novacor LVAS, the Company's ability to raise funding needed to complete its clinical programs and other risks detailed in the Company's filings with the U.
The combination of durability and smaller size of the Novacor II LVAS is expected to result in less traumatic surgery, faster recovery, and higher quality of life for patients," said Dr.
In 2001, he and Norma agreed that he would enroll in the INTrEPID (Investigation in Non-Transplant Eligible Patients who are Inotrope Dependent) feasibility clinical trial underway at Vanderbilt and other major hospitals to evaluate the Novacor LVAS as treatment for people with severe heart disease who are not candidates for cardiac transplantation.
John Elefteriades, Professor at Yale University and Chief of Cardiovascular Surgery at Yale-New Haven Hospital commented: "After a successful weaning process over four days, the patient underwent removal of the Novacor LVAS which had been instrumental in saving her life.
Arrow also announced that another clinical trial center, Policlinico di San Matteo in Pavia, Italy, implanted its first CorAide(TM) LVAS as part of the study.
Young from The Cleveland Clinic Foundation, as a member of WorldHeart's Clinical Executive Committee for the RELIANT Trial (Randomized Evaluation of the Novacor(R) LVAS In A Non-Transplant Population).
Ventracor is confident of obtaining a significant share of the massive LVAS market, which independent analysts expect to be valued at between $US7.
The RELIANT Trial will evaluate the Novacor LVAS for Destination Therapy use by patients suffering from irreversible left ventricular failure who are not candidates for transplantation.
Financial browser ?
- lump of labour
- Lump of Water
- Lump sum
- Lump Sum Distribution
- Lump-sum distribution
- lump-sum payment
- Lump-Sum Tax
- lump-sum taxes
- Lunch and Learn
- Lutine Bell
- Luxembourg Franc
- Luxembourg Stock Exchange
- Luxembourgish Franc
- Luxury Automobile
- luxury product
- Luxury Tax
- Lyapunov Exponents
- Lyon Terms
- M-1, M-2 and M-3
- Ma Bell
- Maastricht Treaty 1991
- Macanese Pataca
- macaroni defense
- Macaulay duration
Full browser ?